| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0304-3940(01)02583-6 |
| P698 | PubMed publication ID | 11872257 |
| P2093 | author name string | Sato S | |
| Takashima A | |||
| Yamaguchi H | |||
| Sun X | |||
| Park JM | |||
| Murayama M | |||
| Murayama O | |||
| P2860 | cites work | Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin | Q24313571 |
| Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau | Q24320124 | ||
| A molecular mechanism for the effect of lithium on development | Q24629067 | ||
| Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease | Q28236160 | ||
| The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3 | Q29614380 | ||
| Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease | Q29617286 | ||
| Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells | Q29618245 | ||
| In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. | Q34355076 | ||
| Prospective clinicopathologic studies of schizophrenia: accrual and assessment of patients | Q40511323 | ||
| The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. | Q40970988 | ||
| Inhibition of beta-amyloid formation by haloperidol: a possible mechanism for reduced frequency of Alzheimer's disease pathology in schizophrenia | Q44010468 | ||
| Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study | Q48331819 | ||
| Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. | Q48622377 | ||
| Activation of the Wnt signaling pathway: a molecular mechanism for lithium action | Q48958687 | ||
| A topographical study of senile plaques and neurofibrillary tangles in the hippocampi of patients with Alzheimer's disease and cognitively impaired patients with schizophrenia. | Q53206878 | ||
| In Vitro Phosphorylation of the Cytoplasmic Domain of the Amyloid Precursor Protein by Glycogen Synthase Kinase-3β | Q56591577 | ||
| Identification of 5.8 kDa C-terminal fragments of Alzheimer amyloid p protein precursor generated in the lysosomal system | Q58124880 | ||
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 61-64 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | Neuroscience Letters | Q7002625 |
| P1476 | title | Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. | |
| P478 | volume | 321 |
| Q44450079 | Alzheimer's disease: Mental plaque removal |
| Q35663582 | Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer's disease |
| Q49256155 | Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons |
| Q33655621 | An amylin analog used as a challenge test for Alzheimer's disease. |
| Q37576090 | An update on treatment and prevention strategies for Alzheimer's disease |
| Q28571842 | Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1 |
| Q33292558 | Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life |
| Q35839636 | Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease |
| Q54113689 | Could Alzheimer's Disease Originate in the Periphery and If So How So? |
| Q35544962 | Current Treatment for Alzheimer Disease and Future Prospects |
| Q34067487 | Current treatment and recent clinical research in Alzheimer's disease |
| Q41882101 | Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin |
| Q79346218 | Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly |
| Q48505432 | Effects of endogenous beta-amyloid overproduction on tau phosphorylation in cell culture |
| Q35770186 | Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers |
| Q44627986 | FRAT1 peptide decreases Abeta production in swAPP(751) cells |
| Q48546153 | Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. |
| Q21129334 | GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS |
| Q35001040 | GSK-3 in Neurodegenerative Diseases. |
| Q28205921 | GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides |
| Q42748129 | GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration |
| Q40963450 | GSK3 as a Sensor Determining Cell Fate in the Brain |
| Q35790372 | GSK3 inhibitors: development and therapeutic potential |
| Q24683037 | Gleevec inhibits β-amyloid production but not Notch cleavage |
| Q37625466 | Glycogen synthase kinase 3 beta regulates glial glutamate transporter protein expression in the spinal dorsal horn in rats with neuropathic pain |
| Q39289700 | Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein |
| Q24685475 | Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics |
| Q89478137 | Glycogen synthase kinase-3 signaling in Alzheimer's disease |
| Q47738177 | Hesperidin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress in a mouse model of Alzheimer's disease |
| Q48447107 | Hippocampal spatial memory impairments caused by the familial Alzheimer's disease-linked presenilin 1 M146V mutation |
| Q38950480 | In vitro streptozotocin model for modeling Alzheimer-like changes: effect on amyloid precursor protein secretases and glycogen synthase kinase-3. |
| Q48460242 | Inhibition of Wnt signaling induces amyloidogenic processing of amyloid precursor protein and the production and aggregation of Amyloid-β (Aβ)42 peptides |
| Q37317816 | Inhibition of glycogen synthase kinase 3β activity with lithium prevents and attenuates paclitaxel-induced neuropathic pain |
| Q36526315 | Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies |
| Q37264297 | Lithium and cognitive enhancement: leave it or take it? |
| Q48805596 | Lithium chloride increases the production of amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3. |
| Q48447113 | Lithium decreases secretion of Abeta1-42 and C-truncated species Abeta1-37/38/39/40 in chicken telencephalic cultures but specifically increases intracellular Abeta1-38. |
| Q28570472 | Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease |
| Q38412707 | Lithium suppression of tau induces brain iron accumulation and neurodegeneration. |
| Q35928266 | Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy |
| Q35197096 | Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders |
| Q26783344 | Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal |
| Q36281844 | Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics |
| Q48794615 | NSE-controlled carboxyl-terminus of APP gene over-expressing in transgenic mice induces altered expressions in behavior, Abeta-42, and GSK3beta binding proteins |
| Q39558313 | Neuroglobin attenuates Alzheimer-like tau hyperphosphorylation by activating Akt signaling. |
| Q42751805 | Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. |
| Q35212429 | Neuroprotective action of lithium in disorders of the central nervous system |
| Q44286092 | Neuroprotective properties of valproate: potential benefit for AD and tauopathies |
| Q38118901 | Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease |
| Q48548992 | PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. |
| Q35097358 | Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein |
| Q38608683 | Personalized Medicine and Resurrected Hopes for the Management of Alzheimer's Disease: A Modular Approach Based on GSK-3β Inhibitors. |
| Q51246561 | Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease. |
| Q42683578 | Protection of neurons from apoptosis by apolipoprotein E-containing lipoproteins does not require lipoprotein uptake and involves activation of phospholipase Cgamma1 and inhibition of calcineurin |
| Q42102101 | Regulation of cell survival mechanisms in Alzheimer's disease by glycogen synthase kinase-3 |
| Q37517959 | Review of lithium effects on brain and blood |
| Q48695359 | Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution |
| Q36012200 | Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease |
| Q35142950 | Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta |
| Q48397223 | Synergistic effects of GSK-3β and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats |
| Q53651197 | Tau and GSK3beta dephosphorylations are required for regulating Pin1 phosphorylation. |
| Q39584144 | The Effects of Astilbin on Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease |
| Q37035378 | The GSK3 hypothesis of Alzheimer's disease |
| Q38259593 | The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain |
| Q34065890 | The aspartate-257 of presenilin 1 is indispensable for mouse development and production of beta-amyloid peptides through beta-catenin-independent mechanisms |
| Q37211285 | The association between small vessel infarcts and the activities of amyloid-β peptide degrading proteases in apolipoprotein E4 allele carriers. |
| Q24651407 | The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis |
| Q28277009 | The ups and downs of Wnt signaling in prevalent neurological disorders |
| Q24626017 | Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder |
| Q57741905 | Transcriptomic profiles of Wnt3a and insulin in primary cultured rat cortical neurones |
| Q38101982 | Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes |
| Q29616159 | WNT and beta-catenin signalling: diseases and therapies |
| Q38113139 | Wnt and lithium: a common destiny in the therapy of nervous system pathologies? |
Search more.